Abstract

Epogam capsules (Scotia) contain oil from the seed of the evening primrose which is rich in the essential fatty acid linoleic acid and its metabolite gamolenic (gamma-linolenic) acid. Epogam is licensed for use to relieve symptoms in atopic eczema, and is claimed to act at a fundamental metabolic level in this disease. Conventional treatment of eczema is often unsatisfactory, and any claim of an advance must be taken seriously. How well founded are the claims made for Epogam?